1. Home
  2. DOUG vs MDWD Comparison

DOUG vs MDWD Comparison

Compare DOUG & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Douglas Elliman Inc.

DOUG

Douglas Elliman Inc.

HOLD

Current Price

$1.87

Market Cap

162.3M

Sector

Real Estate

ML Signal

HOLD

Logo MediWound Ltd.

MDWD

MediWound Ltd.

HOLD

Current Price

$16.48

Market Cap

212.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DOUG
MDWD
Founded
1911
2000
Country
United States
Israel
Employees
N/A
N/A
Industry
Building operators
Medicinal Chemicals and Botanical Products
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.3M
212.1M
IPO Year
2021
2013

Fundamental Metrics

Financial Performance
Metric
DOUG
MDWD
Price
$1.87
$16.48
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$36.00
AVG Volume (30 Days)
472.1K
58.1K
Earning Date
05-05-2026
05-20-2026
Dividend Yield
N/A
N/A
EPS Growth
118.68
N/A
EPS
N/A
N/A
Revenue
$955,578,000.00
N/A
Revenue This Year
N/A
$48.92
Revenue Next Year
N/A
$35.04
P/E Ratio
$10.94
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$14.90
52 Week High
$3.20
$22.51

Technical Indicators

Market Signals
Indicator
DOUG
MDWD
Relative Strength Index (RSI) 46.92 43.32
Support Level $1.55 $16.31
Resistance Level $2.06 $18.49
Average True Range (ATR) 0.12 0.54
MACD 0.01 -0.02
Stochastic Oscillator 13.04 19.89

Price Performance

Historical Comparison
DOUG
MDWD

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.

About MDWD MediWound Ltd.

MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Share on Social Networks: